Preoperative treatment of anemic women with epoetin beta

Larson, Barbro; Bremme, Katarina; Clyne, Naomi; Nordström, Lars

doi:10.1034/j.1600-0412.2001.080006559.x

Cited by 15 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38,39,41,54 Eighteen RCTs assessed ESA with oral iron vs oral iron therapy ( Table 1). [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50] Seven RCTs assessed ESA and intravenous iron vs intravenous iron therapy ( Table 2). [51][52][53][54][55][56][57] One trial compared ESA with oral and intravenous iron vs oral iron therapy.…”

Section: Characteristics Of Included Trialsmentioning

confidence: 99%

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis

Kei

Mistry

Curley

et al. 2019

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

Purpose Iron restricted anemia is prevalent in surgical patients and is associated with an increased risk of allogeneic red blood cell (RBC) transfusion and adverse events. Treatment of anemia includes oral and intravenous iron and erythropoiesis stimulating agents (ESAs). More recent studies have focused on the use of intravenous iron as the primary approach to treating anemia. Nevertheless, the optimal treatment strategy for anemia remains to be established. Our primary objective was to evaluate the efficacy and safety of ESA and iron therapy relative to iron therapy alone in reducing RBC transfusion in surgical patients. Source We searched the Cochrane Library, MEDLINE, EMBASE, and ClinicalTrials.gov from inception to May 2018. We included randomized-controlled trials in which adult surgical patients received an ESA and iron, vs iron

show abstract

Section: Characteristics Of Included Trialsmentioning

confidence: 99%

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis

Kei

Mistry

Curley

et al. 2019

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

“…In two randomized, controlled studies including 81 mildly anemic women who underwent total hysterectomy, women who received recombinant human erythropoietin (rHuEPO) once weekly for 3–4 weeks, plus oral iron supplementation, had significantly higher preoperative hemoglobin (Hb) levels and lower requirements for ABT than those who received only oral iron supplementation 2,3 . Similar results were obtained in a prospective, nonrandomized study of 120 anemic women undergoing gynecological surgery for benign diseases, who were treated preoperatively with rHuEPO at different cumulative doses 4 .…”

Section: Introductionmentioning

confidence: 99%

Preoperative intravenous iron administration corrects anemia and reduces transfusion requirement in women undergoing abdominal hysterectomy

Díez-Lobo¹,

Fisac-Martín

Bermejo-Aycar

et al. 2007

Transfus Alt Transfus Med

View full text Add to dashboard Cite

SUMMARY We prospectively investigated the utility of preoperative intravenous (IV) iron treatment to increase hemoglobin (Hb) levels and reduce the need for transfusion in women with iron deficiency anemia (IDA) or iron deficiency (ID) scheduled for elective abdominal hysterectomy. Seventy‐five women with ID or IDA were enrolled in the study. Women having their surgical procedure at least 1 month after preoperative assessment received IV iron sucrose during 2–4 weeks (IV iron group, n = 31). Women having their surgical procedure a few days after preoperative assessment did not receive IV iron (control group, n = 44). At baseline, there were no differences between the two groups in terms of weight or age, prevalence of anemia, Hb levels or iron laboratory parameters. IV iron sucrose (760 ± 290 mg) increased preoperative Hb (ΔHb: 2.2 ± 1.2 g/dL; P < 0.001) and reduced postoperative transfusion rates when compared with the control group (32%vs. 0%, respectively; P < 0.001). In addition, fewer women from the IV iron group were anemic on postoperative day 21 (23%vs. 68%, respectively; P < 0.01). No life‐threatening iron sucrose adverse effect was observed. Because of the rapid increase in Hb levels, IV iron sucrose administration seems to be an effective approach for treating preoperative anemia and reducing transfusion rates in this female population.

show abstract

Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery

Kaufner

Heymann

Henkelmann

et al. 2020

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Preoperative treatment of anemic women with epoetin beta

Abstract: We found that a significantly greater increase in Hb was achieved with iron in combination with EPO, although in most cases iron only seemed to be as efficacious as iron+EPO in correcting anemia in myoma patients pre-operatively.

Cited by 15 publications

References 15 publications

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis

Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis

Preoperative intravenous iron administration corrects anemia and reduces transfusion requirement in women undergoing abdominal hysterectomy

Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery

Contact Info

Product

Resources

About